Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|April 14, 2009
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Liqi He, Todd Clarke, et al.
Journal of Medicinal Chemistry|April 14, 2009
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Todd Clarke, Liqi He, et al.
European Journal of Pharmacology|April 26, 2017
Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodentsRick L Pieschl, Regina Miller, Kelli M Jones, et al.
ACS Medicinal Chemistry Letters|January 21, 2017
Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor AgonistsMatthew D Hill, Haiquan Fang, H Dalton King, et al.
Plos One|July 29, 2016
The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of SchizophreniaLinda J Bristow, Amy E Easton, Yu-Wen Li, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in ratsSnjezana Lelas, Harvey Wong, Yu-Wen Li, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase InhibitorKevin W Gillman, John E Starrett, Michael F Parker, et al.
Journal of Medicinal Chemistry|December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonistRichard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
Journal of Medicinal Chemistry|June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with SchizophreniaDalton King, Christiana Iwuagwu, Jim Cook, et al.
Pageof 4